Lane Simonian
Contributor since: 2015
Articles
Cassava Sciences And Alzheimer's Disease: A Precipitous Path
Anavex's Blarcamesine: Why It May Treat Alzheimer's Disease
Regulatory Decisions: COVID-19 Vaccine Winners And Losers
Shaky Prospects For Eli Lilly's Donanemab For Alzheimer's Disease
Hypotheses Underlying Alzheimer's Drug Development
Pathways Impacting Alzheimer's Disease Drug Development
Amylyx And ALS: Muddied Results
Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease
Anavex 2-73, GV-971, Cyclo Therapeutics, East Asian Herbs: Antioxidants In The Treatment Of Alzheimer's Disease
Cassava Sciences And Alzheimer's Disease: Unravelling Some Of The Puzzle
Moderna, BioNTech, And Novavax And The Shrinking Coronavirus Vaccine Market
Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease
Anavex 2-73 (Blarcamesine) And The Treatment Of Rett Syndrome: An Important Step Forward
Cassava Sciences: Credibility Issues
Anti-Amyloid Drugs: The Failure Of Success
Cassava Sciences And Alzheimer's Disease: Making Something Out Of Nothing Or Making Nothing Out Of Something
Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease
Cassava Sciences: On The Defense Once Again
Cortexyme: Positive Lessons To Be Learned From Disappointing Results
Novavax: Excellent Vaccine, Questionable Management
Cassava Sciences And Alzheimer's Disease: Raising Doubts
Novavax: The Finish Line Keeps Getting Extended
Detours In The Golden Age Of Alzheimer's Drug Stock Investments
Biogen And Alzheimer's Disease: Closer To Resolution
The Post-Biogen, Post-Amyloid World For Alzheimer's Disease
How The FDA Got It Wrong In Approving Biogen's Aducanumab For Alzheimer's Disease
Annovis And Alzheimer's Disease: Fraught With Potential And Uncertainty
Biogen, Cassava Sciences, And A Comparative Perspective On Treatment Of Alzheimer's Disease
Anavex, Cyclo Therapeutics, And Green Valley: Stalling The Progression Of Alzheimer's Disease
Anavex And Cassava Sciences: Closer To An Understanding Of Alzheimer's Disease
Eli Lilly And Alzheimer's Disease: The Number Games
Biogen And The Politics Of Alzheimer's Disease
Cyclo Therapeutics: A Potential Gem In The Fight Against Alzheimer's Disease
Cassava Sciences' Simufilam For Alzheimer's Disease: We Don't Know Yet
Treating The Causes Of Alzheimer's Disease: The Case For Anavex 2-73
AB Science's Masitinib: An Uncertain Success For Alzheimer's Disease
Biogen And Alzheimer's Disease: The Saga Continues
Anavex 2-73 And GV-971: Turning The Tide Against Alzheimer's Disease
Cassava Sciences' Sumifilam: The Limits To Biomarker Studies In Alzheimer's Disease
Anti-Amyloid Drugs: The Advantages Of Alzheon's ALZ-801 Over Biogen's Aducanumab